Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market: Research and Analysis for 2024-2033

An advanced therapy medicinal product contract development and manufacturing organization (CDMO) is a specialized service provider that assists in the development and manufacturing of advanced therapy medicinal products. The objective of an advanced therapy medicinal product CDMO is to provide the expertise, infrastructure, and resources required for advanced therapy medicinal product development and manufacturing.

Sizing and Forecast

The advanced therapy medicinal product contract development and manufacturing organization (CDMO) market size has grown rapidly in recent years. It will grow from $4.55 billion in 2023 to $5.30 billion in 2024 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to the increasing number of ATMP clinical trials, rising awareness and belief among researchers regarding the benefits of advanced therapy, the presence of several ATMP CDMOs, increasing efforts to develop novel therapies for various diseases, and supportive government initiatives.

The advanced therapy medicinal product contract development and manufacturing organization (CDMO) market size is expected to see rapid growth in the next few years. It will grow to $9.85 billion in 2028 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to the high investment of CDMOs, a growing number of emerging players in the cell and gene therapy (CGT) sector, increasing grants and investments for the development of cell and gene therapies, increasing pharmaceutical R&D spending, increasing number of clinical trials for ATMPs. Major trends in the forecast period include advancements in AAV biomanufacturing facilities, expansion of cell and gene therapy manufacturing, technological advancements in cell and gene therapy, increasing need for access to advanced platforms and technologies, and incorporating advanced technologies such as CRISPR and next-generation sequencing for heightened accuracy.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Segmentation & Regional Insights

The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market covered in this report is segmented –

1) By Product: Gene Therapy, Cell Therapy, Tissue Engineered

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Indication: Oncology, Cardiology, Central Nervous System And Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology And Inflammation, Ophthalmology, Hematology

North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15719&type=smp

Major Driver Impacting Market Growth

The increasing number of clinical trials is expected to propel the growth of the advanced therapy medicinal products CDMO market going forward. Clinical trials are research studies conducted in humans to evaluate the safety and efficacy of medical interventions such as drugs, treatments, devices, or preventive measures. Clinical trial numbers are rising to meet the increasing demand for innovative treatments and to address a growing global disease burden. With the use of advanced therapy medicinal products, the demand for CDMO manufacturing services rises, leveraging specialized expertise and infrastructure. Clinical trial data aids in optimizing manufacturing, ensuring scalability, and quality maintenance to meet larger clinical and commercial needs. For instance, in November 2023, according to the Association of the British Pharmaceutical Industry, a UK-based trade association, the overall number of industry clinical trials initiated in the UK per year increased marginally by 4.3%, from 394 in 2021 to 411 in 2022. Therefore, the increasing number of clinical trials is driving the growth of the advanced therapy medicinal products CDMO market.

Key Industry Players

Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market are Thermo Fisher Scientific Inc., Merck KGaA, Resonac Corporation, Lonza Group AG, Catalent Inc. , Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions

The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market report table of contents includes: